Gene therapy for tritanopia — the AAV-mediated OPN1SW gene delivery for blue-yellow color vision deficiency restoration representing the fastest-growing therapeutic modality in the inherited color blindness treatment landscape — creates the most clinically transformative market segment, with the Tritanopia Treatment Market reflecting gene therapy as the premium innovation commercial...